Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation

References

• Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 2004;117:3415–3425.
   PubMed Web of Science ®Google Scholar
• Hempel D, Sierko E, Wojtukiewicz MZ. Protease-activated receptors: Biology and role in cancer. Postepy Hig Med Dosw 2016;70:775–786.
   Web of Science ®Google Scholar
• Li Z, Delaney MK, O’Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010;30:2341–2349.
   PubMed Web of Science ®Google Scholar
• Falet H, Barkalow KL, Pivniouk VI, Barnes MJ, Geha RS, Hartwig JH. Roles of SLP-76, phosphoinositide 3-kinase, and gelsolin in the platelet shape changes initiated by the collagen receptor GPVI/FcR gamma-chain complex. Blood 2000;96:3786–3792.
   PubMed Web of Science ®Google Scholar
• Cosemans JM, Munnix IC, Wetzker R, Heller R, Jackson SP, Heemskerk JW. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 2006;108:3045–3052.
   PubMed Web of Science ®Google Scholar
• Wu CC, Wu SY, Liao CY, Teng CM, Wu YC, Kuo SC. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation. Br J Pharmacol 2010;161:643–658.
   PubMed Web of Science ®Google Scholar
• Moore SF, Hunter RW, Hers I. Protein kinase C and P2Y12 take center stage in thrombin-mediated activation of mammalian target of rapamycin complex 1 in human platelets. J Thromb Haemost 2014;12:748–760.
   PubMed Web of Science ®Google Scholar
• Heraud JM, Racaud-Sultan C, Gironcel D, Albigès-Rizo C, Giacomini T, Roques S, Martel V, Breton-Douillon M, Perret B, Chap H. Lipid products of phosphoinositide 3-kinase and phosphatidylinositol 4’,5’-bisphosphate are both required for ADP-dependent platelet spreading. J Biol Chem 1998;273:17817–17823.
   PubMed Web of Science ®Google Scholar
• Ampofo E, Müller I, Dahmke IN, Eichler H, Montenarh M, Menger MD, Laschke MW. Role of protein kinase CK2 in the dynamic interaction of platelets, leukocytes and endothelial cells during thrombus formation. Thromb Res 2015;136:996–1006.
   PubMed Web of Science ®Google Scholar
• Aslan JE, Tormoen GW, Loren CP, Pang J, McCarty OJ. S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood 2011;118:3129–3136.
   PubMed Web of Science ®Google Scholar
• Weyrich AS, Denis MM, Schwertz H, Tolley ND, Foulks J, Spencer E, Kraiss LW, Albertine KH, McIntyre TM, Zimmerman GA. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007;109:1975–1983.
   PubMed Web of Science ®Google Scholar
• Sikka P, Bindra VK. Newer antithrombotic drugs. Indian J Crit Care Med. 2010;14:188–195.
   PubMedGoogle Scholar
• Jackson SP, Schoenwaelder SM. Antiplatelet therapy: In search of the ‘magic bullet’. Nat Rev Drug Discov 2003;2:775–789.
   PubMed Web of Science ®Google Scholar
• Yi W, Li Q, Shen J, Ren L, Liu X, Wang Q, He S, Wu Q, Hu H, Mao X, Zhu L. Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161. PLoS One 2014;9:e102394.
   PubMed Web of Science ®Google Scholar
• Arooj M, Sakkiah S, Cao Gp, Lee KW. An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes. PLoS One 2013;8:e60470.
   PubMed Web of Science ®Google Scholar
• Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S–6392S.
   PubMed Web of Science ®Google Scholar
• Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861–6869.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835–844.
   PubMed Web of Science ®Google Scholar
• Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood 2016;128:574–583.
   PubMed Web of Science ®Google Scholar
• Ott GR, Cheng M, Learn KS, Wagner J, Gingrich DE, Lisko JG, Curry M, Mesaros EF, Ghose AK, Quail MR, Wan W, Lu L, Dobrzanski P, Albom MS, Angeles TS, Wells-Knecht K, Huang Z, Aimone LD, Bruckheimer E, Anderson N, Friedman J, Fernandez SV, Ator MA, Ruggeri BA, Dorsey BD. Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). J Med Chem 2016;59:7478–7496.
   PubMed Web of Science ®Google Scholar
• Hart S, Novotny-Diermayr V, Goh KC, Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C, Madan B, Nagaraj H, Jayaraman R, Pasha KM, Ethirajulu K, Chng WJ, Mustafa N, Goh BC, Benes C, McDermott U, Garnett M, Dymock B, Wood JM. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther 2013;12:151–161.
   PubMed Web of Science ®Google Scholar
• Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA, Xu Q. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res. 2015;75:446–455.
   PubMed Web of Science ®Google Scholar
• Shao Z, Bao Q, Jiang F, Qian H, Fang Q, Hu X. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo. PLoS One 2015;10:e0132655.
   PubMed Web of Science ®Google Scholar
• Casella JF, Flanagan MD, Lin S. Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change. Nature 1981;293:302–305.
   PubMed Web of Science ®Google Scholar
• Malek AM, Izumo S. Mechanism of endothelial cell shape change and cytoskeletal remodeling in response to fluid shear stress. J Cell Sci. 1996;109:713–726.
   PubMed Web of Science ®Google Scholar
• Laschke MW, Vollmar B, Menger MD. The dorsal skinfold chamber: window into the dynamic interaction of biomaterials with their surrounding host tissue. Eur Cell Mater 2011;22:147–164.
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Verbeuren TJ, Vallez MO, Lameire NH, De Buyzere M, Vanhoutte PM. Off-line analysis of red blood cell velocity in renal arterioles. J Vasc Res 2000;37:26–31.
   PubMed Web of Science ®Google Scholar
• Broze GJ Jr, Yin ZF, Lasky N. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost 2001;85:747–748.
   PubMed Web of Science ®Google Scholar
• Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, Kaplanski S, Farnarier C. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998;92:1259–1267.
   PubMed Web of Science ®Google Scholar
• Bae JS, Kim YU, Park MK, Rezaie AR. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase. J Cell Physiol 2009;219:744–751.
   PubMed Web of Science ®Google Scholar
• Ampofo E, Später T, Müller I, Eichler H, Menger MD, Laschke MW. The marine-derived kinase inhibitor fascaplysin exerts anti-thrombotic activity. Mar Drugs 2015;13:6774–6791.
   PubMed Web of Science ®Google Scholar
• Cohen P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem 2001;268:5001–5010.
   Google Scholar
• Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010;9:956–970.
   PubMed Web of Science ®Google Scholar
• Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett 2012;319:1–7.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312–3318.
   PubMed Web of Science ®Google Scholar
• Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012;4:a011189.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 2003;278:30725–30731.
   PubMed Web of Science ®Google Scholar
• Christodoulou J, Sadler PJ, Tucker A. 1H NMR of albumin in human blood plasma: drug binding and redox reactions at Cys34. FEBS Lett 1995;376:1–5.
   PubMed Web of Science ®Google Scholar
• Redlich H, Vickers J, Lösche W, Heptinstall S, Kehrel B, Spangenberg P. Formation of platelet-leukocyte conjugates in whole blood. Platelets 1997;8:419–425.
   PubMed Web of Science ®Google Scholar
• Klinkhardt U, Harder S. Flow cytometric measurement of platelet-leukocyte aggregates: A possible target to monitor platelet function? Semin Thromb Hemost. 2005;31:400–403.
   PubMed Web of Science ®Google Scholar
• McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997;100:S97–S103.
   PubMed Web of Science ®Google Scholar
• Caron A, Théorêt JF, Mousa SA, Merhi Y. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardiovasc Pharmacol 2002;40:296–306.
   PubMed Web of Science ®Google Scholar
• Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol. 2010;30:2357–2361.
   PubMed Web of Science ®Google Scholar
• Lova P, Paganini S, Hirsch E, Barberis L, Wymann M, Sinigaglia F, Balduini C, Torti M. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. J Biol Chem 2003;278:131–138.
   PubMed Web of Science ®Google Scholar
• Bombeli T1, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: Evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 1998;187:329–339.
   Google Scholar
• Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001;276:7614–7620.
   PubMed Web of Science ®Google Scholar
• Zerfaoui M, Suzuki Y, Naura AS, Hans CP, Nichols C, Boulares AH. Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction. Cell Signal 2008;20:186–194.
   PubMed Web of Science ®Google Scholar
• Brouard S, Berberat PO, Tobiasch E, Seldon MP, Bach FH, Soares MP. Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis. J Biol Chem 2002;277:17950–17961.
   PubMed Web of Science ®Google Scholar
• Minhajuddin M, Fazal F, Bijli KM, Amin MR, Rahman A. Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. J Immunol 2005;174:5823–5829.
   PubMed Web of Science ®Google Scholar
• Minhajuddin M, Bijli KM, Fazal F, Sassano A, Nakayama KI, Hay N, Platanias LC, Rahman A. Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells. J Biol Chem 2009;284:4052–4061.
   PubMed Web of Science ®Google Scholar